New drug tegavivint takes on tough lymphoma in early trial
Disease control
Recruiting now
This early-phase trial is testing a drug called tegavivint in about 18 people with large B-cell lymphoma that has come back or not responded to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The main goals are to find a safe dose and …
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC